MUHC Medical Grand Rounds 5/2/2023

Title: "Innovations in lipid management"
Speaker: Dr. George Thanassoulis

Educational Objectives:
To briefly review the importance of LDL-C and apoB in ASCVD; To examine the available evidence on novel therapies in lipid management; To describe the role of RNA antisense technology and siRNA technology for the management of lipoprotein disorders; To provide an overview of new molecules and approaches in development for dyslipidemia

Biosketch:
Dr. Thanassoulis is Director of Preventive and Genomic Cardiology at the MUHC and Professor of Medicine at McGill University. His clinical interests are in cardiovascular prevention, dyslipidemia (specifically lipoprotein[a]) and premature coronary artery disease. He currently runs the MUHC Family Heart Clinic for patients with premature CAD and their families with the goal of optimizing their preventive care. His research interests are in the genetics of aortic valve stenosis where he leads an international consortium investigating the role of genomic variation in this disease. This work has culminated in the recently launched CAVS trial that will evaluate the role of targeted Lp(a) lowering in aortic stenosis. He is also working on developing new approaches to optimize cardiovascular prevention in young individuals. He is the co-chair of the 2021 CCS Dyslipidemia Guideline Committee.